A case report on bortezomib-induced paralytic ileus

Abstract

Bortezomib is the first anticancer proteasome inhibitor used in the initial treatment of multiple myeloma in combination with cyclophosphamide and dexamethasone. Subcutaneous and intravenous forms of bortezomib are available. The common adverse drug reactions (ADRs) associated with bortezomib include peripheral neuropathy, fatigue, neuralgia, dizziness, diarrhea, constipation, and abdominal pain. Paralytic ileus is a rare ADR of bortezomib. We report the case of a patient with multiple myeloma who developed paralytic ileus and presented with abdominal distension and constipation; all of which resolved with medical attention once the medication was stopped, indicating a clear causal link.